% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Kebir:863990,
      author       = {Kebir, Sied and Schaub, Christina and Junold, Nina and
                      Hattingen, Elke and Schäfer, Niklas and Steinbach, Joachim
                      P. and Weyerbrock, Astrid and Hau, Peter and Goldbrunner,
                      Roland and Galldiks, Norbert and Weller, Johannes and Mack,
                      Frederic and Tzaridis, Theophilos and Bähr, Oliver and
                      Seidel, Clemens and Schlegel, Uwe and Schmidt-Graf,
                      Friederike and Rohde, Veit and Borchers, Christian and
                      Tabatabai, Ghazaleh and Hänel, Mathias and Sabel, Michael
                      and Gerlach, Rüdiger and Krex, Dietmar and Belka, Claus and
                      Vatter, Hartmut and Proescholdt, Martin and Glas, Martin and
                      Herrlinger, Ulrich},
      title        = {{B}aseline {T}1 hyperintense and diffusion-restricted
                      lesions are not linked to prolonged survival in
                      bevacizumab-treated glioblastoma patients of the {GLARIUS}
                      trial},
      journal      = {Journal of neuro-oncology},
      volume       = {144},
      number       = {3},
      issn         = {1573-7373},
      address      = {Dordrecht [u.a.]},
      publisher    = {Springer Science + Business Media B.V},
      reportid     = {FZJ-2019-03906},
      pages        = {501-509},
      year         = {2019},
      abstract     = {PurposeThe phase II GLARIUS trial assigned patients with
                      newly diagnosed, O-6-methylguanine-DNA methyltransferase
                      promoter non-methylated glioblastoma to experimental
                      bevacizumab/irinotecan (BEV/IRI) or standard temozolomide
                      (TMZ). To identify subpopulations with a particularly
                      favorable course, we assessed the prognostic potential of
                      magnetic resonance imaging (MRI) markers before treatment
                      onset.MethodsMRIs at baseline (before treatment onset) were
                      analyzed for T1-hyperintense and diffusion-restricted
                      lesions; as well as the presence of both hyperintense and
                      diffusion-restricted (double positive) lesions. The MRI
                      findings were correlated with overall and progression-free
                      survival.ResultsMRI scans were evaluable in $71\%$ of the
                      GLARIUS modified intention-to-treat population (n = 121
                      of 170; 88 patients in the BEV/IRI arm, and 33 patients in
                      the TMZ control arm). Diffusion-restricted and T1
                      hyperintense lesions were present in $60\%$ and $65\%$ of
                      patients in BEV/IRI arm, while $57\%$ and $63\%$ were found
                      in the TMZ arm, respectively. Double positive lesions were
                      found in $37\%$ of BEV/IRI patients and in $39\%$ of TMZ
                      patients. Neither the presence of T1-hyperintense,
                      diffusion-restricted lesions, nor double positive lesions
                      were associated with improved survival.ConclusionsBaseline
                      T1-hyperintense and diffusion-restricted lesions are not
                      suitable to predict progression-free or overall survival of
                      patients treated with bevacizumab/irinotecan or
                      temozolomide.},
      cin          = {INM-3},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406},
      pnm          = {572 - (Dys-)function and Plasticity (POF3-572)},
      pid          = {G:(DE-HGF)POF3-572},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:31325144},
      UT           = {WOS:000487899900008},
      doi          = {10.1007/s11060-019-03246-4},
      url          = {https://juser.fz-juelich.de/record/863990},
}